The Trump administration today announced steps drug manufacturers must take to lower prescription drug prices in the U.S. to "most favored nation" pricing, the lowest cost paid for the same medications in other countries. The steps include providing MFN prices to all Medicaid beneficiaries; requiring manufacturers to stipulate that they will not offer other developed nations better prices for new drugs than those offered in the U.S.; providing manufacturers an avenue to sell medicines directly to patients at a price no higher than the best available in developed nations; and using trade policy to support manufacturers in raising prices internationally provided that higher revenues abroad are reinvested directly into lowering prices for Americans.

Headline
The Centers for Medicare & Medicaid Services announced in a memo April 21that it is delaying implementation of the Medicare Part D portion of the Better…
Headline
President Trump April 18 signed an executive order to accelerate research into psychedelic drugs for the treatment of serious mental illnesses, calling…
Headline
The U.S. Court of Appeals for the 5th Circuit April 9 affirmed rulings by a Mississippi district court that rejected requests by Novartis and PhRMA to enjoin…
Headline
The White House April 2 issued a proclamation implementing additional tariffs on certain patented pharmaceutical products and ingredients. The order imposes a…
Headline
The Centers for Medicare & Medicaid Services April 2 released a final rule on policy and technical changes to Medicare Advantage, the Medicare Prescription…
Headline
The AHA commented today on the Centers for Medicare & Medicaid Services’ proposed rule on the Global Benchmark for Efficient Drug Pricing Model, or…